Key result
Aspirin resistance prevalence varied by assay (13.3% to 22.9%) in 105 acute ischemic stroke patients, and its presence was not significantly associated with poor clinical outcome.
Why the study?
Does aspirin resistance measured by different platelet function assays correlate with poor clinical outcomes in patients with acute ischemic stroke?
Observational (n=105)
Does aspirin resistance measured by different platelet function assays correlate with poor clinical outcomes in patients with acute ischemic stroke?
The detection of aspirin resistance in acute ischemic stroke is highly assay-dependent and does not appear to significantly correlate with poor clinical outcomes.
Should not yet guide aspirin resistance testing in acute ischemic stroke; leaves open its prognostic value in larger prospective cohorts.
Background: Aspirin resistance (AR) in platelet function assays showed substantial variation depending on the methods used to evaluate it. Methods: In this study, we prospectively compared the results of Multiplate impedance platelet aggregometry (IPA) with those of light transmission aggregometry (LTA) and VerifyNow ® system in determination of the prevalence of aspi- rin resistance (AR) and investigated the correlation between its presence and poor outcome (modifi ed Rankin scale >2) in 105 patients with aspirin after acute ischemic stroke (AIS). Results: After 5 days of using aspirin, 15 patients (14.3%) were clas- sifi ed as aspirin-resistance with the use of IPA, 24 patients (22.9%) by the LTA, and 14 patients (13.3%) by VerifyNow. Good agreement between the results of IPA and VerifyNow, was found (R=0.674, P<0.01). The concordance rate of AR detection was high between VerifyNow and IPA (k=0.72, P<0.01), albeit quite low between LTA and IPA. Regarding on its infl uence on clini- cal outcome after AIS, there wasn't any signifi cant relationship between occurrence of poor outcome and the presence of AR in three platelet function assays. Conclusion: This study reveals that the incidence of AR in AIS might be highly test-specifi c. IPA seems to be similar to VerifyNow as a platelet function test. (Korean J Stroke 2012;14:35-42)
No takes yet. Share an insight, caveat, or question.
Yoo et al. (2012) conducted an observational in Acute ischemic stroke (n=105). Aspirin resistance vs. Absence of aspirin resistance was evaluated on Poor outcome (modified Rankin scale >2). Aspirin resistance prevalence varied by assay (13.3% to 22.9%) in 105 acute ischemic stroke patients, and its presence was not significantly associated with poor clinical outcome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: